Study Shows Pembrolizumab Active in Relapsed Refractory Populations

Jonathan Gerber, MD of Levine Cancer Institute, gives an overview of a clinical study that shows pembrolizumab is active in relapsed refractory populations of AML at the 58th ASH Annual Meeting in San Diego, CA.